Education
About Us
Working with TipRanks
Follow Us
Turnstone Biologics Corp. (TSBX)
NASDAQ:TSBX
TSBX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.37 - $4.81
Previous CloseN/A
Volume78.23K
Average Volume (3M)280.03K
Market Cap
$8.92M
Enterprise Value-$30.87M
Total Cash (Recent Filing)$14.43M
Total Debt (Recent Filing)$2.72M
Price to Earnings (P/E)―
Beta3.08
Next Earnings
Mar 20, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding23,128,454
10 Day Avg. Volume128,442
30 Day Avg. Volume280,028
Standard Deviation0.32
R-Squared0.06
Alpha-0.15
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)65.12
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-3.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.87
Enterprise Value/Ebitda0.40
Forecast
1Y Price Target
$0.70Price Target Upside84.21% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
Turnstone Biologics Corp. News
PremiumCompany Announcements
Turnstone Biologics Halts TIDAL-01 Studies Amid Market Woes
PremiumCompany Announcements
Turnstone Biologics Faces Financial and Operational Challenges
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company guides to a cash runway into the second quarter of 2026, providing a degree of financial stability.
Next-Generation Program PotentialThe company’s pre-clinical, next-generation TIL program, TIDAL-02, could deliver value to whomever picks up Turnstone’s mantle.
Strategic RestructuringThe company's restructuring and prioritization should help extend the cash runway, alleviating near-term pressure for fund raising prior to important data update.
Bears Say
Clinical Program DiscontinuationTurnstone Biologics announced the discontinuation of their lead (and sole) clinical program, TIDAL-01.
Financial ChallengesWith the removal of TIDAL-01 from estimates, the price target has been reduced to $1 from $3 and the MP rating is reiterated.
Workforce ReductionA workforce reduction by 60% was recently implemented, indicating potential challenges within the company.
---
Ownership Overview
32.32%
Insiders
3.10% Mutual Funds
25.98% Other Institutional Investors
35.92% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TSBX FAQ
What was Turnstone Biologics Corp.’s price range in the past 12 months?
Turnstone Biologics Corp. lowest stock price was $0.36 and its highest was $4.80 in the past 12 months.
What is Turnstone Biologics Corp.’s market cap?
Turnstone Biologics Corp.’s market cap is $8.92M.
When is Turnstone Biologics Corp.’s upcoming earnings report date?
Turnstone Biologics Corp.’s upcoming earnings report date is Mar 20, 2025 which is in 16 days.
How were Turnstone Biologics Corp.’s earnings last quarter?
Turnstone Biologics Corp. released its earnings results on Nov 12, 2024. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.86 by $0.12.
Is Turnstone Biologics Corp. overvalued?
According to Wall Street analysts Turnstone Biologics Corp.’s price is currently Undervalued.
Does Turnstone Biologics Corp. pay dividends?
Turnstone Biologics Corp. does not currently pay dividends.
What is Turnstone Biologics Corp.’s EPS estimate?
Turnstone Biologics Corp.’s EPS estimate is -0.77.
How many shares outstanding does Turnstone Biologics Corp. have?
Turnstone Biologics Corp. has 23,128,454 shares outstanding.
What happened to Turnstone Biologics Corp.’s price movement after its last earnings report?
Turnstone Biologics Corp. reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.86. Following the earnings report the stock price went down -8.621%.
Which hedge fund is a major shareholder of Turnstone Biologics Corp.?
Currently, no hedge funds are holding shares in TSBX
---
Company Description
Turnstone Biologics Corp.
Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The Company is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. Its selected TIL approach focuses on selecting and expanding potent tumor-reactive T cells to overcome the limitations of bulk TILs. Its pipeline includes TIDAL-01 and TIDAL-02. Its lead selected TIL product candidate, TIDAL-01, utilizes an unbiased identification and functional screening process to isolate and selectively expand the breadth of tumor-reactive TILs from the patient¿s tumor. Its next selected TIL program, TIDAL-02, is being designed to encompass a streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
---
TSBX Stock 12 Month Forecast
Average Price Target
$0.70
▲(84.21% Upside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Kura Oncology
―
Allogene Therapeutics
―
Precision BioSciences
―
Best Analysts Covering TSBX
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-76.23%
reiterated a buy rating 7 months ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -76.23% per trade.
---